论文部分内容阅读
利用6天SRCA研究了130例次不同实体瘤对肿瘤化疗药物的敏感性。试验可评价率为87.6％。其中对43例患者进行了 SRCA前瞻性临床研究,19例(44.2％)获CR或PR;12例虽化疗显效但随后加入其它治疗因素而无法评价。试验结果提示 SRCA具有较高的准确性和重现性。根据本文拟定的动物试验和临床反应评价标准,SRCA临床反应真阳性率为 91.2％(31/34);真阴性率为 88.9％(8/9);总符合率 90.7％(39/43)。
Using a 6-day SRCA, the sensitivity of 130 different solid tumors to tumor chemotherapeutic drugs was studied. The test rate is 87.6%. Of these, 43 patients underwent a SRCA prospective clinical study, 19 (44.2%) received CR or PR, and 12 patients could not be evaluated despite the marked effect of chemotherapy but subsequent addition of other treatment factors. The test results suggest that SRCA has high accuracy and reproducibility. According to the animal testing and clinical response evaluation standards proposed in this paper, the true positive rate of clinical response in SRCA was 91.2% (31/34); the true negative rate was 88.9% (8/9); the overall compliance rate was 90.7% (39/43).